PURPOSE: We tested the hypothesis that changes in the diabetic ocular environment facilitate the development of endogenous bacterial endophthalmitis (EBE). METHODS: C57BL/6J mice were rendered diabetic with streptozotocin (STZ) for 1, 3, or 5 months' duration. Diabetic and age-matched nondiabetic mice were tail vein-injected with 10(8) CFU of Klebsiella pneumoniae, a common cause of EBE in diabetics. After either 2 or 4 days postinfection, the EBE incidence was assessed by electroretinography, histology, bacterial counts, and myeloperoxidase ELISAs. Blood-retinal barrier (BRB) permeability in uninfected diabetic mice also was determined. RESULTS: No cases of EBE were observed among the 1-month diabetic group. Extending the time from diabetes induction to 3 months resulted in a 23.8% EBE incidence after 2 days, and a 22% incidence after 4 days. The incidence of EBE increased to 27% in the 5-month diabetic group. Infected eyes had an average 8.01 × 10(2) and 6.19 × 10(4) CFU/eye for the 3- and 5-month diabetic groups, respectively. There was no significant difference in BRB permeability between control and 1-month uninfected diabetic mice. However, 3- and 5-month diabetic mice had significantly greater BRB permeability than control mice. These results suggested that increasing the time from STZ diabetes induction to 3 and 5 months resulted in an ocular environment more conducive to the development of EBE. CONCLUSIONS: These results demonstrated a correlation between an increase in BRB permeability and an increase in EBE incidence, supporting the hypothesis that diabetic ocular changes contribute to the development of EBE.
PURPOSE: We tested the hypothesis that changes in the diabetic ocular environment facilitate the development of endogenous bacterial endophthalmitis (EBE). METHODS: C57BL/6J mice were rendered diabetic with streptozotocin (STZ) for 1, 3, or 5 months' duration. Diabetic and age-matched nondiabetic mice were tail vein-injected with 10(8) CFU of Klebsiella pneumoniae, a common cause of EBE in diabetics. After either 2 or 4 days postinfection, the EBE incidence was assessed by electroretinography, histology, bacterial counts, and myeloperoxidase ELISAs. Blood-retinal barrier (BRB) permeability in uninfected diabeticmice also was determined. RESULTS: No cases of EBE were observed among the 1-month diabetic group. Extending the time from diabetes induction to 3 months resulted in a 23.8% EBE incidence after 2 days, and a 22% incidence after 4 days. The incidence of EBE increased to 27% in the 5-month diabetic group. Infected eyes had an average 8.01 × 10(2) and 6.19 × 10(4) CFU/eye for the 3- and 5-month diabetic groups, respectively. There was no significant difference in BRB permeability between control and 1-month uninfected diabeticmice. However, 3- and 5-month diabeticmice had significantly greater BRB permeability than control mice. These results suggested that increasing the time from STZdiabetes induction to 3 and 5 months resulted in an ocular environment more conducive to the development of EBE. CONCLUSIONS: These results demonstrated a correlation between an increase in BRB permeability and an increase in EBE incidence, supporting the hypothesis that diabetic ocular changes contribute to the development of EBE.
Authors: Mario Giobbia; Pier Giorgio Scotton; Antonella Carniato; Mario Cruciani; Antonio Farnia; Enrico Daniotti; Giorgio Scarpa; Alberto Vaglia Journal: Int J Infect Dis Date: 2003-09 Impact factor: 3.623
Authors: Andrea L Moyer; Raniyah T Ramadan; Billy D Novosad; Roger Astley; Michelle C Callegan Journal: Invest Ophthalmol Vis Sci Date: 2009-03-05 Impact factor: 4.799
Authors: Frederick C Miller; Phillip S Coburn; Mursalin Md Huzzatul; Austin L LaGrow; Erin Livingston; Michelle C Callegan Journal: Prog Retin Eye Res Date: 2019-05-28 Impact factor: 21.198
Authors: Roger A Astley; Phillip S Coburn; Salai Madhumathi Parkunan; Michelle C Callegan Journal: Prog Retin Eye Res Date: 2016-05-03 Impact factor: 21.198
Authors: C Motta; M Salmeri; C D Anfuso; A Amodeo; M Scalia; M A Toscano; G Giurdanella; M Alberghina; G Lupo Journal: Infect Immun Date: 2013-12-09 Impact factor: 3.441
Authors: Phillip S Coburn; Brandt J Wiskur; Frederick C Miller; Austin L LaGrow; Roger A Astley; Michael H Elliott; Michelle C Callegan Journal: PLoS One Date: 2016-05-19 Impact factor: 3.240